IDEAYA Biosciences is a clinical-stage precision medicine oncology company that is dedicated to improving lives through transformative precision medicines. They focus on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Their goal is to develop therapeutics that are first-in-class and/or best-in-class, with a primary focus on synthetic lethality, which is an emerging class of precision medicine targets.

Headquartered in South San Francisco, California, IDEAYA combines the expertise of their talented scientists with an entrepreneurial spirit to foster innovation and deliver game-changing medicines to patients. They have a strong commitment to discovering and developing innovative new therapies for cancer patients. IDEAYA's scientists employ an integrated approach for the discovery and development of biomarkers and therapeutics to address unmet needs in cancer.

Their capabilities include target and biomarker discovery integrated with small molecule and protein degrader therapeutics, covering the entire journey from early discovery to clinical development. By leveraging the concept of synthetic lethality, IDEAYA aims to pursue historically undruggable targets, indirectly inhibiting target proteins in a patient population selected for treatment based on genetic alterations of the tumor biology. Overall, IDEAYA Biosciences is dedicated to revolutionizing precision medicine and making a significant impact on the lives of cancer patients